Quiz: Treatments for presbyopia coming soon

Publication
Poll
Optometry Times JournalNovember digital edition 2020
Volume 12
Issue 11

quick quiz

This quiz accompanies THIS article from our November issue

1. What is the prevalence of presbyopia in the U.S.?

a. 5,000,000
b. 10,500,000
c. 50,000,000
d. 110,000,000

2. Miotics have few side effects.

a. True
b. False

3. Which of these devices uses pinhole optics (PHO)?

Revision Raindrop
b. Karama Inlay
c. FOV Tears
d. Allergan Presbysol
e. B and D

4. Which of these is not a pharmaco-refractive product?

a. Oraisis CSF-1
b. Presbyopia Therapies PRX-100
c. Allergan AGN
d. Eyenovia Micro-dose
e. All are pharmaco-refractive

5. What is the most common ingredient in current pharmaceutical drops for presbyopia being tested?

a. Dexamethasone
b. Pilocarpine
c. Bromfenac
d. Tropicamide
e. None of the above

6. Which of these is a device?

a. Oraisis CSF-1
b. Presbyopia Therapies PRX-100
c. Allergan AGN
d. Eyenovia Micro-dose
e. FOV Tears

Which is an active ingredient in PRX-100?

a. Pilocarpine
b. Tropicamide
c. Oxymetazoline
d. Polyethylene glycol
e. Diclofenac

Click here to see the correct answers

This quiz accompanies THIS article from our November issue

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Another drop in the presbyopia bucket: Dr Bloomenstein shares his excitement for the FDA approval of Vizz
Marc Bloomenstein, OD, FAAO, is a clinical investigator in the trials and overviews the transformative potential of LNZ100.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
© 2025 MJH Life Sciences

All rights reserved.